Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.44
(
0.00%
)
Bitcoin
70,209.01
(
0.44%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 199657

Wednesday, 11/16/2016 5:24:48 PM

Wednesday, November 16, 2016 5:24:48 PM

Post# of 257262
GILD’s Momelotinib goes 1-for-2 in SIMPLIFY/1-2 trials: #msg-126609986.

http://finance.yahoo.com/news/gilead-announces-top-line-results-211500046.html

The nominal success was in SIMPLIFY-1, where Momelotinib was non-inferior to Jakafi in JAK-naïve patients.

The failure was in SIMPLIFY-2, where Momelotinib was not superior to BAT (Best Available Therapy) in patients previously treated with—but not refractory to—Jakafi.

Momelotinib is the drug GILD picked up in the 2012 buyout of YMI (#msg-82377008).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now